title: Increased Duration of Heating Boosts Local Drug Deposition during Radiofrequency Ablation in Combination with Thermally Sensitive Liposomes (ThermoDox) in a Porcine Model.
abstract: BACKGROUND
  Radiofrequency ablation (RFA) is used for the local treatment of liver cancer. RFA is effective for small (<3 cm) tumors, but for tumors > 3 cm, there is a tendency to leave viable tumor cells in the margins or clefts of overlapping ablation zones. This increases the possibility of incomplete ablation or local recurrence. Lyso-Thermosensitive Liposomal Doxorubicin (LTLD), is a thermally sensitive liposomal doxorubicin formulation for intravenous administration, that rapidly releases its drug content when exposed to temperatures >40°C. When used with RFA, LTLD releases its doxorubicin in the vasculature around the zone of ablation-induced tumor cell necrosis, killing micrometastases in the ablation margin. This may reduce recurrence and be more effective than thermal ablation alone.
  
  
  OBJECTIVE
  The purpose of this study was to optimize the RFA procedure used in combination with LTLD to maximize the local deposition of doxorubicin in a swine liver model. Pigs were anaesthetized and the liver was surgically exposed. Each pig received a single, 50 mg/m2 dose of the clinical LTLD formulation (ThermoDox®). Subsequently, ablations were performed with either 1, 3 or 6 sequential, overlapping needle insertions in the left medial lobe with total ablation time of 15, 45 or 90 minutes respectively. Two different RFA generators and probes were evaluated. After the final ablation, the ablation zone (plus 3 cm margin) was dissected out and examined for doxorubicin concentration by LC/MS and fluorescence.
  
  
  CONCLUSIONS
  The mean Cmax of plasma total doxorubicin was 26.5 μg/ml at the end of the infusion. Overall, increased heat time from 15 to 45 to 90 minutes shows an increase in both the amount of doxorubicin deposited (up to ~100 μg/g) and the width of the ablation target margin to which doxorubicin is delivered as determined by tissue homogenization and LC/MS detection of doxorubicin and by fluorescent imaging of tissues.
authors.affiliation: Celsion Corporation, Lawrenceville, NJ, United States of America.
authors.forename: Christine E
authors.initials: CE
authors.lastname: Swenson
authors.affiliation: Medical University of South Carolina, Charleston, SC, United States of America.
authors.forename: Dieter
authors.initials: D
authors.lastname: Haemmerich
authors.affiliation: PreClinical Research Services, Inc., Fort Collins, CO, United States of America.
authors.forename: Donald H
authors.initials: DH
authors.lastname: Maul
authors.affiliation: PreClinical Research Services, Inc., Fort Collins, CO, United States of America.
authors.forename: Bridget
authors.initials: B
authors.lastname: Knox
authors.affiliation: Colorado State University Animal Cancer Center, Fort Collins, CO, United States of America.
authors.forename: Nicole
authors.initials: N
authors.lastname: Ehrhart
authors.affiliation: Celsion Corporation, Lawrenceville, NJ, United States of America.
authors.forename: Robert A
authors.initials: RA
authors.lastname: Reed
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage; D006358:Hot Temperature; D006979:Hyperthermia, Induced; D008081:Liposomes; D008114:Liver Neoplasms, Experimental / Q000628:therapy*; D023421:Models, Animal; D013552:Swine
chemical_list: D000903:Antibiotics, Antineoplastic; D008081:Liposomes; D004317:Doxorubicin